Welcome to our dedicated page for Reneo Pharmaceuticals news (Ticker: RPHM), a resource for investors and traders seeking the latest updates and insights on Reneo Pharmaceuticals stock.
The RPHM news page on Stock Titan offers an archive of announcements and corporate updates related to Reneo Pharmaceuticals, Inc. and its transformation through a merger with OnKure, Inc. Historically, Reneo used news releases to report clinical progress in rare genetic mitochondrial diseases, financial results, and later, key steps in its strategic review and merger process. These items provide a detailed record of how a mitochondrial disease–focused pharmaceutical company evolved into the public vehicle for a precision oncology business.
Earlier news items cover Reneo’s clinical-stage activities, including the pivotal STRIDE study of mavodelpar in primary mitochondrial myopathies (PMM), the STRIDE AHEAD open-label extension, and scientific presentations on mitochondrial bioenergetics. Releases describe the scientific rationale for targeting peroxisome proliferator-activated receptor delta (PPARδ) and the company’s focus on rare genetic mitochondrial diseases associated with impaired ATP production. Subsequent updates document the negative STRIDE trial outcome, suspension of mavodelpar development, workforce reductions, and the initiation of a strategic alternatives process.
Later news is centered on corporate and transaction events. These include the announcement of a definitive merger agreement with OnKure, a clinical-stage biopharmaceutical company focused on precision oncology, stockholder approval of the merger, a reverse stock split, and the closing of the transaction. Post-closing communications from OnKure describe the combined company’s focus on PI3Kα-targeted precision medicines, including the OKI-219 program in a Phase 1 trial for solid tumors.
By reviewing this news archive, readers can follow the full narrative arc from Reneo’s rare disease development efforts through its merger into OnKure Therapeutics, Inc. For ongoing updates about the operating precision oncology company, users should look to news issued under the OnKure Therapeutics, Inc. name and its Nasdaq ticker symbol OKUR.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Reneo Pharmaceuticals (RPHM)?
What is the market cap of Reneo Pharmaceuticals (RPHM)?
